BioLineRx BLRX announced today that BL-7010, an orally available treatment for
celiac disease, was found to be safe and well tolerated in pre-clinical
studies conducted to date. The new findings were delivered in an oral
presentation by Professor Elena Verdú, Division of Gastroenterology,
Department of Medicine, McMaster University, Hamilton, Ontario, at the Better
Life for Coeliacs 2012 Conference, held in Helsinki, Finland from
September 6th-9th. In her talk, Prof. Verdú also
presented previously disclosed pre-clinical data demonstrating that
BL-7010 reduces gluten toxicity, which were published in the in leading
medical journal Gastroenterology.
In pre-clinical studies BL-7010 was found to be safe, well tolerated and
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in